Modality
Peptide
MOA
AHRant
Target
FGFR
Pathway
Checkpoint
Endometrial Ca
Development Pipeline
Preclinical
~Jun 2019
→ ~Sep 2020
Phase 1
~Dec 2020
→ ~Mar 2022
Phase 2
Jun 2022
→ Dec 2028
Phase 2Current
NCT04792628
912 pts·Endometrial Ca
2022-06→2028-12·Completed
912 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-12-032.7y awayPh3 Readout· Endometrial Ca
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P2/3
Complet…
Catalysts
Ph3 Readout
2028-12-03 · 2.7y away
Endometrial Ca
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04792628 | Phase 2/3 | Endometrial Ca | Completed | 912 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| BII-5449 | Biogen | Phase 3 | FXIa | |
| Elratapinarof | Halozyme | Phase 2 | C5 | |
| Nidaratamab | Exelixis | Phase 3 | FLT3 | |
| NTL-2576 | Intellia | NDA/BLA | SGLT2 | |
| Tixatapinarof | Recursion | Approved | FGFR |